EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma

Agnieszka E Zając iD, Piotr Rutkowski, Anna Szumera-Ciećkiewicz, Jakub Piątkowski, Paweł Teterycz, Emanuela Palmerini iD, Aurélie Dutour, Justyna Tuziak-Klym iD, Michał Wągrodzki, Andrzej Pieńkowski, Andrzej Tysarowski iD, Marco Gambarotti iD und 9 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27042018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Agnieszka E Zając und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Pola…. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Regional Center for Digital Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chondrosarcoma (ChS) is a rare bone malignancy with heterogeneous behavior, the molecular and immunological background of which remains unknown. No effective systemic treatment for advanced ChS patients is available. The aim of this study was to develop an immune–mutational classification of ChS and to search for novel prognostic factors and molecular targets. We performed an immunological–molecular profiling of 99 patients diagnosed with primary ChS G1–G3 and dedifferentiated ChS. An expression of 20 immune response markers was assessed by IHC and targeted the next-generation sequencing of 409 genes was performed. Immunological and mutational profiles were correlated with overall survival using a multivariate LASSO-penalized Cox model. Three immunophenotypes were described—“cold” (IMP1), “hot” (IMP2), and “intermediate” (IMP3). IMP1 was the most prevalent in G1 cases, while IMP2 was the most prevalent in dedifferentiated cases. IDH1/2 or TP53 mutations were associated with high-grade ChS (FDR < 0.05). IMP2 was characterized by a higher number of immune infiltrates in the central region of the tumor (HR: 3.3; CI: 1.13–9.8; p < 0.05). IDH1 mutations were present most often in IMP2 cases (HR: 3.8; CI: 1.75–8.1; p < 0.001). Tumor size, dedifferentiated subtype, IDH1 mutation and the presence of IMP2 were identified as independent negative prognostic survival factors in ChS. An immune–mutational classification system for ChS patients was proposed, which may be used to identify those potentially suited for immunotherapy combined with IDH-mutant inhibitors in future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaBone NeoplasmsBiomarkers, TumorHumansFemalePrognosisMutationMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

chondrosarcomaimmunological profilingimmunotherapymolecular profilingtumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, A. Pawińskiego 5A, 02-106 Warsaw, Poland.
  • Regional Center for Digital Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136 Bologna, Italy.

ORCID-Profile: Agnieszka E Zając, Emanuela Palmerini, Justyna Tuziak-Klym, Andrzej Tysarowski, Marco Gambarotti, Alberto Righi, Giovanna Magagnoli, Toni Ibrahim, Jean-Yves Blay, Paweł Golik, Anna M Czarnecka

Förderung

  • National Science Centre
  • Regional Center for Digital Medicine

Zitieren

APA

Zając, A. E., Rutkowski, P., Szumera-Ciećkiewicz, A., Piątkowski, J., Teterycz, P., Palmerini, E., Dutour, A., Tuziak-Klym, J., Wągrodzki, M., Pieńkowski, A., Tysarowski, A., Gambarotti, M., Frega, G., Pierini, M., Righi, A., Magagnoli, G., Jean-Denis, M., Ibrahim, T., Blay, J. Y., …, & Czarnecka, A. M. (2026). Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27042018

Vancouver

Zając AE, Rutkowski P, Szumera-Ciećkiewicz A, Piątkowski J, Teterycz P, Palmerini E, et al. Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27042018

BibTeX
@article{Zajc2026,
  author = {Zając, Agnieszka E and Rutkowski, Piotr and Szumera-Ciećkiewicz, Anna and Piątkowski, Jakub and Teterycz, Paweł and Palmerini, Emanuela and Dutour, Aurélie and Tuziak-Klym, Justyna and Wągrodzki, Michał and Pieńkowski, Andrzej and Tysarowski, Andrzej and Gambarotti, Marco and Frega, Giorgio and Pierini, Michela and Righi, Alberto and Magagnoli, Giovanna and Jean-Denis, Myriam and Ibrahim, Toni and Blay, Jean-Yves and Golik, Paweł and Czarnecka, Anna M},
  title = {Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27042018}
}
Kostenlos starten →